AI assistant
Q32 Bio Inc. — Director's Dealing 2018
Apr 4, 2018
34891_dirs_2018-04-04_442200ff-c3a4-4b41-a8b3-ffa1b3cd158d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-04-02
Reporting Person: SHAH MAHENDRA (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-02 | Common Stock | C | 659742 | $0.00 | Acquired | 659742 | Indirect |
| 2018-04-02 | Common Stock | A | 500000 | $16.00 | Acquired | 1159742 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-02 | Series B Preferred Stock | $ | C | 659742 | Disposed | Common Stock (659742) | Indirect |
Footnotes
F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
F2: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.